Prognostic significance of oncofetal antigens in patients with ovarian cancer.
The prognostic significance of elevated oncofetal antigens, namely carcinoembryonic antigen (CEA), alphafetoprotein (AFP), and beta subunit of human chorionic gonadotrophin (beta HCG) were studied in 39 patients with cancer of the ovary. At low cut-off levels, (CEA greater than 2.5 micrograms/l, AFP greater than 5 micrograms/l, and beta HCG greater than 3 IU/l) the median survival was 21 months in patients with one or more positive markers compared to greater than 43 months in patients without markers. At high cut-off points (namely CEA greater than 10 micrograms/l, AFP greater than 10 micrograms/l and beta HCG greater than 10 IU/l), the median survival of patients having one or more positive markers was 10 months compared to greater than 46 months in patients with no markers. Using linear regression and Logrank analysis, the difference between the observed and expected death rate was significant (P less than 0.05 at low cut-off levels, and less than 0.01 at high cut-off levels). These results indicate that patients who have one or more positive oncofetal markers on presentation are likely to have a significantly worse prognosis than patients without markers. Moreover, higher levels of oncofetal markers are associated with correspondingly worse prognosis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D006063:Chorionic Gonadotropin / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D010446:Peptide Fragments / Q000097:blood*; D000509:alpha-Fetoproteins / Q000032:analysis*
D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D000509:alpha-Fetoproteins